Title: Hydroxyurea
CAS Registry Number: 127-07-1
Additional Names: Hydroxycarbamide
Trademarks: Droxia (BMS); Hydrea (BMS); Litalir (BMS)
Molecular Formula: CH4N2O2
Molecular Weight: 76.05
Percent Composition: C 15.79%, H 5.30%, N 36.84%, O 42.08%
Line Formula: H2NCONHOH
Literature References: Ribonuleotide reductase inhibitor; blocks DNA synthesis and repair. Induces fetal hemoglobin production in patients with sickle cell anemia. Prepn: W. F. C. Dressler, R. Stein, Ann. 150, 242 (1869). Alternate route: P. J. Graham, US 2705727 (1955 to Du Pont). Symposium on mechanism of action and clinical experience in cancer: Semin. Oncol. 19, Suppl. 9, 1-116 (1992). Clinical trials in sickle cell crises in adults: S. Charache et al., N. Engl. J. Med. 332, 1317 (1995); in children: T. R. Kinney et al., Blood 94, 1550 (1999). Review of clinical pharmacokinetics: P. R. Gwilt, W. G. Tracewell, Clin. Pharmacokinet. 34, 347-358 (1998); of pharmacology and potential therapeutic indications: P. Navarra, P. Preziosi, Crit. Rev. Oncol. Hematol. 29, 249-255 (1999). Clinical trial in essential thrombocythemia: C. N. Harrison et al., N. Engl. J. Med. 353, 33 (2005).
Properties: Needles from alc, mp 133-136°. Freely sol in water, hot alcohol.
Melting point: mp 133-136°
Therap-Cat: Antineoplastic; in treatment of sickle cell anemia.
Keywords: Antineoplastic.
Hyenanchin Hygrine Hygrophylline Hymecromone Hymecromone O,O-Diethyl Phosphorothioate

Structural formula
Systematic (IUPAC) name
Clinical data
Trade names Apo-Hydroxyurea, Droxia, Hydrea
AHFS/Drugs.com International Drug Names
MedlinePlus a682004
Licence data EMA:Link, US FDA:link
Pregnancy cat. D (AU) D (US)
Legal status Prescription Only (S4) (AU) -only (CA) POM (UK) -only (US)
Routes Oral
Pharmacokinetic data
Metabolism Hepatic (to CO2 and urea)
Half-life 2-4 hours
Excretion Renal and lungs
CAS number 127-07-1 YesY
ATC code L01XX05
PubChem CID 3657
DrugBank DB01005
ChemSpider 3530 YesY
KEGG D00341 YesY
ChEBI CHEBI:44423 YesY
NIAID ChemDB 006310
Chemical data
Formula CH4N2O2 
Mol. mass 76.0547 g/mol
 YesY (what is this?)  (verify)

Hydroxycarbamide (INN, BAN) or hydroxyurea (USAN, this generic name is also in common usage in Australia. Brand names include Hydrea and Droxia) is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.